The dramatically particular safety and efficacy outcomes from the DAPA-CKD trial, which showed that treatment with the sodium-glucose transporter 2 (SGLT2) inhibitor dapagliflozin vastly reduce…
Add patients with power kidney illness with or without diabetes to the rising list of those who win proven have the benefit of therapy with…